Non-invasive photobiomodulation treatment in an Alzheimer Disease-like transgenic rat model.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and in vitro laboratory experiment
PubMed 35265207 · doi:10.7150/thno.70756
What was done
Researchers evaluated the therapeutic effects and molecular mechanisms of long-term continuous-wave low-level laser photobiomodulation (PBM) in a transgenic rat model of Alzheimer's disease (AD). Starting at 2 months of age, rats received non-invasive PBM for 2 minutes, 3 times per week for 16 months. Outcomes included cognitive performance on behavioral tests, amyloid plaque burden, tau hyperphosphorylation, neuronal loss, apoptosis, spine damage, and synaptic loss. Underlying mechanisms were assessed via immunofluorescence, western blotting, mass spectrometry, primary cortical and hippocampal cell cultures, and hemoglobin alpha (Hbα) knockdown experiments.
What was found
The abstract reports no quantitative values, effect sizes, or confidence intervals. It qualitatively reports that PBM significantly improved memory performance, reduced amyloid plaques and tau hyperphosphorylation, and attenuated neuronal degeneration, spine damage, and synaptic loss. Mechanistically, PBM regulated glial cell polarization, inhibited neuroinflammation, preserved mitochondrial fission/fusion dynamics, suppressed oxidative damage to DNA, proteins, and lipids, and enhanced microglial recruitment around plaques via the IL-3/IL-3Rα pathway. Hbα knockdown abolished the neuroprotective effects of PBM.
Why it matters
The study identifies neuronal hemoglobin and astrocytic-microglial IL-3 signaling as potential mediators of photobiomodulation's neuroprotective actions in a preclinical AD model, offering mechanistic targets for non-invasive light therapy development.
Limits
This is an animal study in transgenic rats, which does not fully replicate human AD pathology or clinical progression. The abstract does not report sample sizes, specific laser parameters (wavelength, power density, fluence), or quantitative effect sizes. Translatability to humans is constrained by differences in skull thickness, light penetration depth, and disease etiology.
Cited by
- supports Photobiomodulation reduces and reverses misfolding and accumulation of alpha-synuclein, tau protein, and beta-amyloid in neurodegenerative disease models.